Treatment of septicaemia in immunocompromised patients with ceftazidime or with tobramycin and cefuroxime, with special reference to renal effects.
Fifty-two immunocompromised patients with suspected septicaemia were randomized on 61 occasions to treatment with ceftazidime or with tobramycin and cefuroxime. Most (90%) of the patients had haematological malignancies and were neutropenic (granulocytes less than 1 X 10(9)/1 in 40 of the 61 episodes). Blood cultures were positive in 22 (39%) febrile episodes and in four other instances positive cultures were obtained from other sources. Clinical cure or improvement was noted in 10 of 12 culture verified infections in the tobramycin and cefuroxime group and 11 of 14 episodes in the ceftazidime-group. The effect on the kidney of the two antibiotic regimens was studied by following the serum levels of creatinine, urea and beta 2-microglobulin and the urinary excretion of alanine aminopeptidase, N-acetyl-beta-D-glucosaminidase (beta-NAG) and beta 2-microglobulin. No clinically important renal side effects were observed. However, an increase in the urinary excretion of AAP was seen in both groups with significantly greater elevation in the tobramycin and cefuroxime group. Urinary beta-NAG increased only in the tobramycin and cefuroxime group.
Rödjer
S
S
Alestig
K
K
Bergmark
J
J
Bergström
T
T
Hultberg
B
B
Jagenburg
R
R
Olaisson
L
L
Trollfors
B
B
Westin
J
J
D000328:Adult; D000368:Aged; D002442:Ceftazidime / Q000097:blood / Q000627:therapeutic use*; D002444:Cefuroxime / Q000097:blood / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000097:blood; D007668:Kidney / Q000187:drug effects*; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D018805:Sepsis / Q000097:blood / Q000188:drug therapy*; D014031:Tobramycin / Q000097:blood / Q000627:therapeutic use
D002442:Ceftazidime; D002444:Cefuroxime; D014031:Tobramycin